Target intelligence / Profile preview

Hemoglobin subunit gamma-1 and Hemoglobin subunit gamma-2 (HBG1/HBG2)

Target
HBG1/HBG2
Molecular classification
Other
01

Overview

Hemoglobin subunit gamma-1 (HBG1) and Hemoglobin subunit gamma-2 (HBG2) are highly homologous protein subunits that, together with alpha-globin subunits, assemble to form fetal hemoglobin (HbF, a2g2). During fetal development, HbF serves as the primary oxygen carrier, possessing a higher affinity for oxygen than adult hemoglobin (HbA, a2b2) to facilitate oxygen transfer across the placenta. Shortly after birth, a developmental switch occurs where the expression of HBG1 and HBG2 is silenced by transcriptional repressors such as BCL11A and LRF/ZBTB7A, and adult beta-globin (HBB) expression is activated. In patients with beta-hemoglobinopathies, such as sickle cell disease (SCD) and beta-thalassemia, mutations in the HBB gene lead to defective adult hemoglobin, causing severe clinical manifestations like vaso-occlusive crises and chronic anemia.

HBG1 and HBG2 have emerged as major therapeutic targets, as inducing their expression to restore HbF levels can functionally compensate for defective beta-globin and prevent the polymerization of sickle hemoglobin. Therapeutic strategies include ex vivo gene editing of autologous hematopoietic stem cells (using CRISPR-Cas9, CRISPR-Cas12a, or base editors) to disrupt repressor binding sites in the HBG1/2 promoters, as seen with investigational therapies like renizgamglogene autogedtemcel, ristoglogene autogetemcel, and OTQ923. Additionally, pharmacological agents such as hydroxyurea, decitabine, and histone deacetylase (HDAC) inhibitors are utilized to epigenetically de-repress HBG1/2 expression and elevate HbF levels.

Other names
Hemoglobin subunit gamma-1Hemoglobin subunit gamma-2Gamma-globinFetal hemoglobin gamma chainHBG1HBG2HbF subunit gammaA-gamma globinG-gamma globinHemoglobin gamma-1 chainHemoglobin gamma-2 chainHemoglobin gamma-A chainHemoglobin gamma-G chain
02

Mechanism of action

Reactivation of fetal hemoglobin (HbF) expression by disrupting transcriptional repressor binding sites (e.g., BCL11A) in the HBG1 and HBG2 promoters via ex vivo gene editing (CRISPR-Cas9, CRISPR-Cas12a, or base editing), or by pharmacological de-repression of the HBG1 and HBG2 promoters using small-molecule HbF inducers (such as DNMT inhibitors, HDAC inhibitors, E3 ligase modulators, or sGC activators).

03

Biological functions

Oxygen transportOxygen bindingGas transportFetal developmentMaintenance of blood oxygen homeostasisOther
04

Disease associations

Sickle cell diseaseBeta-thalassemiaHereditary persistence of fetal hemoglobinAnemiaOther
05

Safety considerations

MyelosuppressionGenotoxicity and cytotoxicityOff-target gene editing effectsMyeloablative conditioning risksInconsistent or variable therapeutic induction levels of HbFRisk of secondary malignancies
06

Interacting drugs

12 more in the full profile.

07

Biomarkers

Fetal hemoglobin (HbF) levelsF-cell percentageHBG1/HBG2 mRNA levelsReticulocyte countMean corpuscular volume (MCV)Total hemoglobin levels

Beyond the preview

Go deeper on Hemoglobin subunit gamma-1 and Hemoglobin subunit gamma-2 (HBG1/HBG2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemoglobin subunit gamma-1 and Hemoglobin subunit gamma-2 (HBG1/HBG2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call